An observational study in Coronary Artery Disease, sponsored by Biotronik AG. Recruiting at 13 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG — 1 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Biotronik SE & Co. KG.
Among the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2020, is one of 20 observational ones, and was the 36th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG is open now, in 7 countries.
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2020.
This study's planned enrollment of 1,106 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 202 across the 17 interventional studies, 528 across the 20 observational. Of the 23 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Biotronik AG, one of the names counted as Biotronik SE & Co. KG. Under that name alone:
Biotronik AG is the lead sponsor of 40 studies on the registry; 2 are open to participants now.
1 of the studies in Coronary Artery Disease by Biotronik SE & Co. KG that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05540223Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).
Patients with symptomatic coronary artery disease needing the treatment of de novo native coronary artery lesions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
Also known as: Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
Freesolve is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
Also known as: Freesolve Sirolimus-Eluting Coronary Resorbable Magnesium Scaffold (RMS) System
Target Lesion Failure (TLF)
The primary endpoint will be Target Lesion Failure (TLF) at 12 months. TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven Target Lesion Revascularization (TLR).
Time frame: 12 months
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No — The primary outcome data will be shared after the publication of it.
Started Nov 2020 (actual). Primary completion is estimated for May 2030, 114 months after the start.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 114 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.